Satya (Nanu) Das, MD, MSCI, is a medical oncologist and hematologist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. He is the lead of the NET program at VICC and is the medical oncology lead for the peptide receptor radionuclide therapy program. His research interests center on gastrointestinal cancer, with a focus on NETs and drug development. He is the principal investigator of several clinical trials in NETs.
Among Dr. Das’s research projects is designing studies for patients with NETs and NECs, utilizing the impairment of DNA damage repair to create new treatment strategies for gastrointestinal cancers and assessing when to optimally sequence PRRT. Clinically, Dr. Das takes care of patients with advanced GI malignancies with a specific interest in those with neuroendocrine tumors and colorectal, pancreatic, and gastric adenocarcinoma. NET patients make up more than 60% of Dr. Das’s practice.
